Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate MiNK Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding MiNK Therapeutics, Inc.’s stock price such as:

• MiNK Therapeutics, Inc.’s current stock price and volume
• Why MiNK Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for INKT from analysts
• INKT’s stock price momentum as measured by its relative strength

About MiNK Therapeutics, Inc. (INKT)

Before we jump into MiNK Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome. It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for auto-immune diseases. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors; and C-Further for the development of PRAME-targeted iNKT cell therapy for pediatric cancers. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Want to learn more about MiNK Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about MiNK Therapeutics, Inc..

MiNK Therapeutics, Inc.’s Stock Price as of Market Close

As of April 24, 2026, 4:00 PM, CST, MiNK Therapeutics, Inc.’s stock price was $10.950.

MiNK Therapeutics, Inc. is up 2.05% from its previous closing price of $10.730.

During the last market session, MiNK Therapeutics, Inc.’s stock traded between $10.430 and $11.510. Currently, there are approximately 4.69 million shares outstanding for MiNK Therapeutics, Inc..

MiNK Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

MiNK Therapeutics, Inc. Stock Price History

MiNK Therapeutics, Inc.’s (INKT) price is currently up 3.99% so far this month.

During the month of April, MiNK Therapeutics, Inc.’s stock price has reached a high of $14.880 and a low of $10.240.

Over the last year, MiNK Therapeutics, Inc. has hit prices as high as $76.000 and as low as $6.340. Year to date, MiNK Therapeutics, Inc.’s stock is down 1.79%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused MiNK Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 24, 2026, there was 1 analyst who downgraded MiNK Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate MiNK Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on MiNK Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about MiNK Therapeutics, Inc. (INKT) by visiting AAII Stock Evaluator.

Relative Price Strength of MiNK Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 24, 2026, MiNK Therapeutics, Inc. has a weighted four-quarter relative price strength of 7.70%, which translates to a Momentum Score of 77 and is considered to be Strong.

Want to learn more about how MiNK Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

MiNK Therapeutics, Inc. Stock Price: Bottom Line

As of April 24, 2026, MiNK Therapeutics, Inc.’s stock price is $10.950, which is up 2.05% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like MiNK Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.